中文名稱:AKR1B10抗體 | 英文名稱:Rabbit Polyclonal AKR1B10 Antibody |
品牌: 艾普蒂 | 產(chǎn)地: 武漢 |
保存條件: Stored at -20°C for 3767 year. Avoid repeated freeze / thaw cycles. | 產(chǎn)品類別: 抗體 |
重組: 否 | 應(yīng)用: WB: IHC-P:?IHC-F:?ICC/IF: IP:FC:ChIP:?ELISA |
種屬反應(yīng)性: Human,Mouse,Rat | 宿主: Rabbit |
偶聯(lián)物: 無 | 靶點(diǎn): AKR1B10 |
WB | 咨詢技術(shù) | Human,Mouse,Rat |
IF | 咨詢技術(shù) | Human,Mouse,Rat |
IHC | 1/25-1/100 | Human,Mouse,Rat |
ICC | 技術(shù)咨詢 | Human,Mouse,Rat |
FCM | 咨詢技術(shù) | Human,Mouse,Rat |
Elisa | 1/2000-1/5000 | Human,Mouse,Rat |
Aliases | HIS; HSI; ARL1; ARL-1; ALDRLn; AKR1B11; AKR1B12 |
WB Predicted band size | 36 kDa |
Host/Isotype | Rabbit IgG |
Antibody Type | Primary antibody |
Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
Species Reactivity | Human |
Immunogen | Fusion protein of human AKR1B10 |
Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
Gel: 10%SDS-PAGE, Lysate: 40 μg, Lane: A549 cells, Primary antibody: P07806(AKR1B10 Antibody) at dilution 1/184, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 5 seconds
The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P07806(AKR1B10 Antibody) at dilution 1/30. (Original magnification: ×200)
The image is immunohistochemistry of paraffin-embedded Human lung cancer tissue using P07806(AKR1B10 Antibody) at dilution 1/30. (Original magnification: ×200)
1. **"AKR1B10 as a biomarker for hepatocellular carcinoma" by Yan et al.**
該研究通過免疫組化分析,證實(shí)AKR1B10在肝癌組織中高表達(dá),提出其作為肝癌早期診斷及預(yù)后的潛在生物標(biāo)志物。
2. **"AKR1B10 overexpression in colorectal cancer and chemoresistance" by Li et al.**
利用Western blot和免疫熒光技術(shù),發(fā)現(xiàn)AKR1B10在結(jié)腸癌中顯著上調(diào),并與5-氟尿嘧啶耐藥性相關(guān),提示其作為治療靶點(diǎn)的可能性。
3. **"AKR1B10 in lung adenocarcinoma: Diagnostic implications" by Wang et al.**
通過組織芯片和免疫組化檢測,發(fā)現(xiàn)AKR1B10在肺腺癌中特異性高表達(dá),可作為區(qū)分腺癌與其他肺部病變的輔助診斷指標(biāo)。
4. **"AKR1B10 expression correlates with breast cancer progression" by Chen et al.**
研究采用免疫組化及生存分析,揭示AKR1B10在乳腺癌中的高表達(dá)與腫瘤轉(zhuǎn)移、復(fù)發(fā)及患者不良預(yù)后顯著相關(guān)。
The AKR1B10 (aldo-keto reductase family 1 member B10) antibody is a key tool for studying the role of AKR1B10. an enzyme implicated in cancer metabolism and chemoresistance. AKR1B10 belongs to the aldo-keto reductase superfamily, which catalyzes the reduction of carbonyl compounds, including toxic aldehydes and ketones, into their corresponding alcohols. Initially identified as a liver-specific protein, AKR1B10 is overexpressed in several cancers, such as hepatocellular carcinoma, lung adenocarcinoma, and breast cancer, where it promotes cell proliferation, detoxification of chemotherapeutic agents (e.g., daunorubicin), and lipid metabolism regulation. Its upregulation is associated with poor prognosis and resistance to therapies.
Antibodies targeting AKR1B10 are widely used in research to detect its expression and localization in tissues or cell lines via techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF). These antibodies help elucidate AKR1B10's functional roles, such as its interaction with retinoid metabolism pathways or involvement in oxidative stress responses. Monoclonal antibodies against AKR1B10 are particularly valuable for specificity in distinguishing it from homologous enzymes like AKR1B1. Additionally, AKR1B10 antibodies hold potential diagnostic value, as elevated protein levels in serum or tissues may serve as biomarkers for early cancer detection or therapeutic monitoring. Ongoing studies explore their utility in targeted therapies to inhibit AKR1B10's oncogenic activity.
成立日期 | 2024-06-24 (2年) | 注冊資本 | 50萬(元) |
員工人數(shù) | 1-10人 | 年?duì)I業(yè)額 | ¥ 100萬以內(nèi) |
主營行業(yè) | 中間體,化學(xué)試劑 | 經(jīng)營模式 | 貿(mào)易,工廠,試劑,定制,服務(wù) |
產(chǎn)品名稱 | 價(jià)格 | 公司名稱 | 報(bào)價(jià)日期 | |
---|---|---|---|---|
¥1600.00 |
VIP10年
|
北京索萊寶科技有限公司
|
2025-08-19 | |
¥1950 |
VIP3年
|
上海滬震實(shí)業(yè)有限公司
|
2025-08-20 | |
詢價(jià) |
VIP3年
|
武漢佰樂博生物技術(shù)有限公司
|
2025-08-20 |